Most commercial insurance plans and Medicare Part D plans cover Repatha, and Medicare Advantage (Part C) plans with drug coverage may also cover it. To find out if your Medicare Advantage or Part D ...

Amgen Inc.’s AMGN new cholesterol-lowering medication, Repatha (evolocumab), a PCSK9 inhibitor, has found a place on CVS Health Corporation’s CVS formulary with CVS Health announcing that Repatha will ...

Amgen (NASDAQ: AMGN) announced that CVS Health (NYSE:CVS) will provide preferred access to Repatha® (evolocumab) through its CVS/caremark commercial formularies. "Ensuring access to Repatha for ...

As 2026 brings the first wave of Medicare drug price negotiations under the Inflation Reduction Act, the landscape for high-cost cardiovascular medications like Repatha (evolocumab) has shifted ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Repatha is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Amgen has announced a price reduction for Repatha (evolocumab), bringing the list price of the therapy to $5,850 per year, ...

Both Repatha and Praluent are used to treat high cholesterol and reduce the risk of certain cardiovascular events. The drugs also have different approved uses in adults and children. Repatha and ...

Amgen announced that all Repatha (evolocumab) devices are now available at a 60% reduced list price. This includes the pre-filled syringe, the SureClick autoinjector, and the Pushtronex device, an ...

Amgen's Repatha was shown to reduce the risk of cardiovascular events, such as cardiovascular death and myocardial infarction, in phase 3 of the FOURIER study. Full results will be presented in March ...